New immunotherapeutic therapeutic approaches

For a long time all attempts to use the body’s own immune response against tumor cells for an effective lung cancer therapy had been without success. The increasing comprehension of the molecular control of the immune system has recently lead to the development of new drugs, the so-called immune checkpoint inhibitors (also called anti-PD1, anti PDL1 antibody), which have a surprisingly good efficacy in various forms of lung cancer. The effectiveness is due to an activation of the body’s own T cells (T-lymphocytes) against the tumor cells.


The first PD1 antibody has already been approved after failure of chemotherapy in squamous cell carcinoma of the lung. In addition to an improved tolerability, the survival of patients with this therapy is better than with chemotherapy.

Also in adenocarcinoma of the lung the approval of such drugs can be expected soon. In trials, they are also tested in small cell lung cancer.

Last update: 07. March 2016 , 11:36

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.